A registry study of elranatamab for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tracks people with relapsed multiple myeloma who are taking elranatamab as part of their regular treatment. It will collect information about how well the medicine works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have relapsed or refractory multiple myeloma
- You have already tried at least three types of treatment: a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), and an anti-CD38 antibody (like daratumumab)
- You are already taking or planning to take elranatamab as part of your regular medical care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This study observes and records infections in adults with multiple myeloma that has returned or stopped responding to previous treatments, who are now being treated with a drug called elranatamab. The goal is to understand how often infections occur and help doctors manage them better.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
Hear when a new TCE-RRMM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.